Clinical Research of Gastonia | Gastonia, NC

Research site

(Unclaimed)

Location

1010 X Ray Drive, Gastonia, North Carolina, United States of America

Site insights

Top conditions

Top treatments

BLU-5937

Astegolimab

Tiotropium

TAK-994

JZP-258

MK-7264

Pitolisant

Gefapixant

Dupilumab

S-600918

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 44 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling

Refractory Chronic Cough

Drug: Placebo

Drug: BLU-5937

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) wh...

Active, not recruiting

Idiopathic Hypersomnia

Excessive Daytime Sleepiness

Drug: Pitolisant

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial...

Active, not recruiting

Idiopathic Pulmonary Fibrosis

Drug: HZN-825

Drug: Placebo

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this...

Active, not recruiting

Diabetes Mellitus, Type 2

Drug: semaglutide

Drug: oral glucose-lowering medications (commercially available)

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling

Crohn's Disease

Drug: Placebo

Drug: Etrasimod

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling

Chronic Obstructive Pulmonary Disease (COPD)

Drug: Astegolimab

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Astegolimab

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Astegolimab

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic...

Enrolling

Idiopathic Hypersomnia

Narcolepsy

Drug: JZP258 (XYWAV)

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling

Asthma

Drug: Placebo

Drug: Lunsekimig

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting

OSA

Drug: AD109

Drug: Placebo

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Inhaled Long-Acting Muscarinic Antagonist

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (ATLAS)

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling

Asthma

Drug: Placebo

Drug: Dupilumab